-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received $20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company developing psychedelics and large pharma- -Advancement of 11 therapeutic programs, including initiation of Recognify’s Phase 2…


Previous articlePsychedelic Medicine Virtual Symposium – 8/28, 9/11, 9/25
Next articlePsychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A